



**The Digital Examiner**  
**[www.prostaid.org](http://www.prostaid.org)**

**“Issue #308” August 2025**

***Hello August***



**Guest Speaker August 20**  
**Navigating Sexual Relationships After Cancer**

**Description:**

An overview of common difficulties in sexual function (ie erectile issues, delayed ejaculation, low desire) after cancer and ways to maintain sexual relationships without reliable erection.



## Chelsea Anderson

Chelsea is a registered provisional psychologist with the College of Alberta Psychologists. Originally from Kelowna, BC, Chelsea completed her Master of Arts in Counselling in 2022 and relocated to Calgary, AB in 2023 to join Dr Lauren Walker at Walker Psychological Inc. While in Kelowna, Chelsea practiced for nearly a decade working with clients with extensive trauma backgrounds, including sexual trauma.

For the past two years, Chelsea has been working under the clinical supervision of Dr Walker, specializing in couples counselling and sex therapy. Chelsea has a special interest in working with cancer survivors and spends some of her time working directly out of the Prostate Cancer Centre. In her private practice, Chelsea works with people to develop healthier relationships with their bodies, whether that is in a sexual context or athletic setting.

Chelsea loves to explore the outdoors by bike, cross-country skis or snowboard. You will often find her training for mountain bike races, or enjoying the calm quiet of fresh snow in the trees. In this way, Chelsea encourages her clients to get curious about their own relationships with moving their bodies!

---

**Starting July 16th, our progressive 50/50 raffle will run each month and the final draw will be held at our 2025 Pathfinder Award event in December.**

**Pool Total To Date Is \$180**



This will be a 6 month consecutive sale of tickets at all of our General meetings. You must buy a ticket in person at one or all of these meetings. All tickets sold will be recorded so that if for any reason you are unable to attend the final draw, you will still be eligible. We will have an electronic paying option as well as cash. The ticket price is 1 for \$5 or 3 for \$10.

**THERE WILL BE NO ONLINE SALES AT ALL ONLY IN PERSON SALES AND ALL SALES ARE FINAL**

AGLC Licence# 733539



## Warriors Lunch

Reminder to all of our Warriors that our next pizza lunch at Bella Roma Pizza in Lakeview is scheduled for **Tuesday August 5th** starting at 11:30 am.

Confirm your attendance and don't forget to bring \$20 to help cover the cost.

RSVP [info@prostaid.org](mailto:info@prostaid.org)

Bella Roma Pizza #17 6449 Crowchild Tr. SW.

**All of our monthly General meetings are in person or via Zoom**

**Location for in person is:**

**CKE Community Centre (1015 73 Ave SW, Calgary, AB)**

**If you are unable to attend in person, you can always join us via Zoom please sign up HERE**

## **Important Notice Please Read**

### **Warriors & Wives Partners and Caregivers**

**Join us on Wednesday, August 20th. We are meeting at CKE starting at 6:00 pm for both the warriors and wives, partners and caregivers in their designated areas.**

**We then will gather in the main hall for our social gathering until our main meeting which starts at 7:30 pm.**

# ***We are in Urgent Need of a Vice President.***

*You can play a vital role in our impactful mission. Your skills and dedication can help shape a brighter future.*

*We will help you grow into this position and "If you believe this is the perfect opportunity for you, we'd love to hear from you*

*Reach out to any of our Board members or connect with me directly at [program.director@prostaaid.org](mailto:program.director@prostaaid.org).*



## **Donate Today**

PROSTAID Calgary is a registered charity that relies on the generosity of its members, supporters and friends to achieve its goals. Tax receipts are issued for all amounts over \$20.00.

Your donations are used to support our monthly journal (the Digital Examiner), our free online video library, our website, our outreach programs and general awareness.

**Donate Today**

## **Connect With Us**

Information  
Phone 403 455 1916  
[info@prostaaid.org](mailto:info@prostaaid.org)  
Brad Sterling  
President  
[president@prostaaid.org](mailto:president@prostaaid.org)

**Connect With Us**

## **Support Groups**

Jim Richardson  
Warriors  
[jim.richardson@telus.net](mailto:jim.richardson@telus.net)  
Wives, Partners & Caregivers  
Newly Diagnosed  
[info@prostaaid.org](mailto:info@prostaaid.org)

**Meeting Info Here**

## **Articles Of Interest**



## DRIVING CHANGE FOR MEN'S HEALTH

The MAN VAN® is Canada's first and only mobile men's health clinic offering FREE PSA (Prostate Specific Antigen) blood testing used for early detection of prostate cancer.

Now serving Edmonton & north for men 50 to 70 years of age


-No appointment necessary

-Testing ages 40 to 70

-Find the next community clinic near you

-15 minutes can save your life!

**MAN VAN UPCOMING CLINICS**



## Scientists uncover immune cells that help prostate cancer resist treatment—and reveal a way to stop them


These cells are typically the immune system's housekeeping crew—engulfing dead cells and responding to infection—but in prostate cancer, some are reprogrammed by tumors to suppress the body's immune responses and promote their own spread.

In follow-up experiments, Mei and his colleagues tested whether blocking these cells could improve treatment. In mice with prostate tumors, they used an antibody to block the SPP1 protein—and found that tumors were more vulnerable to immunotherapy.

[More Info](#)

July 2025  
MedicalXpress

**Immune Cells**




## Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence

Enzalutamide (Xtandi), as a monotherapy and combined with leuprolide, demonstrated positive topline overall survival (OS) results in patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with biochemical recurrence at high risk for metastasis in the phase 3 EMBARK trial (NCT02319837), according to a press release from the developers, Pfizer and Astellas Pharma.

### More Info

July 2025  
Cancernetwork

Enzalutamide



## Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published


Data from both cohorts of the phase 3 TALAPRO-2 trial (NCT03395197) have been published in concurrent publications in *The Lancet*, looking at the combination of talazoparib (Talzenna) plus enzalutamide (Xtandi) in patients with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC)<sup>1</sup> and in those unselected for HRR gene mutations.

In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival (OS) vs enzalutamide alone.

### Study Overview

July 2025  
Urology Times

Phase 3




## Focal Therapy Finding Its Niche for Intermediate-Risk Prostate Cancer

**In men with favorable intermediate-risk disease, focal therapy will emerge as a means of primary disease management, with the goal of mitigating metastatic risk while avoiding the need for radical therapy in the man's lifetime," Dr Taneja noted. There is a general consensus that each patient needs to be assessed for their individual risk factors to ensure the risks don't outweigh the benefits.**

**July 2025  
Renal+Urology**

**Focal**



## Study shows favorable outcomes with guideline-based treatment for localized prostate cancer

**Overall, data showed that for patients with low- to intermediate-risk prostate cancer, the risk of prostate cancer mortality was 6 times lower than the risk of mortality from other causes. Further, in patients with high-risk prostate cancer, the risk of prostate cancer mortality was still 2 times lower than the risk of mortality from other causes.**

**If guideline-recommended treatment is used, most people with prostate cancer will live for many years after diagnosis. That includes active surveillance as an excellent treatment strategy for appropriately selected people.**

**[More Info Here](#)**

**May 2025  
MedicalXpress**

**Favorable Outcome**






## Carotuximab/Apalutamide Shows Tolerability in Metastatic CRPC

Citing an unmet need of resistance to current hormone therapies among patients with prostate cancer, developers designed the study to evaluate carotuximab, a CD105 antagonist, in male patients whose disease has progressed following standard hormone therapies.

### Trial Info

July 2025  
Cancernetwork

**Carotuximab**



## NeuroSafe Technique for Radical Prostatectomy Protects Potency, Continence in Trial

The NeuroSAFE technique involves the intra-operative frozen section examination of the whole neurovascular bundle-adjacent prostate margins to assess whether cancer cells have reached the surgical cut surface. This allows surgeons to make real-time decisions about whether to remove additional tissue to ensure complete cancer removal while preserving nerves.

### Trial Results

July 2025  
Urology Times

**NeuroSafe**






## Exosomes: A Promising Tool for Liquid Biopsy in Prostate Cancer

Prostate cancer (PCa) often manifests insidiously, with most patients being diagnosed at an advanced stage, leading to a poor prognosis. Early detection of PCa can significantly prolong overall survival by impeding the progression of metastasis. A commonly utilized screening method for detecting PCa is the prostate-specific antigen test.

### More Info

March 2025  
XHP Publishing

[Liquid Biopsy](#)



## Bringing you the most up to date information in treatments, support, well-being, and more all in one place


We can help you in achieving the support you're looking for. On the Canadian Prostate Cancer Guide website you can look to find the most up to date information on prostate cancer in one place.

[Learn More Here](#)

### Read about these articles below

- 1-Why some men experience urinary leaks
- 2- Improve Well-being in Distressed Cancer Survivors
- 3-Student designs prostate screening device
- 4-UroActive smart implant for male SUI
- 5-Long-Term Effects of Chemotherapy
- 6-Low-intensity shock-wave therapy for erectile dysfunction
- 7-Targeting the Hedgehog protein's hidden weakness
- 8-Why some prostate tumors resist standard treatments
- 9-ClarityDX
- 10-AI-based tool can 'measure' cancer aggressiveness

## Articles For Everyone



### Why some men experience urinary leaks—or incontinence

Up to 10% of men may experience stress incontinence after prostate surgery due to multiple factors related to the patient's anatomy, prostate cancer and the surgery performed. Ultimately, this leads to a weakened sphincter muscle and laxity of the pelvic floor. The sphincter muscles control the release of urine, and the urethra is the small tube that empties the bladder.

July 2025  
MedicalXpress

Incontinence



### Mindfulness, Tai Chi Improve Wellbeing in Distressed Cancer Survivors

Total Mood Disturbance scores significantly decreased in patients who were randomized into receiving Mindfulness-Based Cancer Recovery and in all patients who received Tai Chi/Qijong treatment.

July 2025  
Renal+Urology

Mindfulness



PRO check. Credit: Devon Tyso

## Student designs prostate screening device to replace traditional examination method

Designed for use by GPs during routine prostate assessments, PRO check allows doctors to evaluate the size and texture of the prostate—two key indicators of potential health issues—in a more objective and consistent way than the traditional digital rectal examination.

### [More Info](#)

July 2025  
MedicaXpress

**Screening**



## FDA, French ANSM greenlight pivotal trial of UroActive smart implant for male SUI

The FDA and the French National Agency for the Safety of Medicines and Health Products (ANSM) have granted an investigational device exemption (IDE) clearance to a pivotal trial of the UroActive smart implant for the treatment of stress urinary incontinence (SUI) in men, UroMems announced in a news release.<sup>1</sup>

According to the company, the UroActive System “is placed around the urethral duct and is controlled based on the patient's activity, without the need for complex manipulation, intending to provide patients with ease of use and a better quality of life than current options.”

### [More Info Here](#)

July 2025  
Urology Times

**Male Implant**



## Researchers Gain New Insight Into Long-Term Effects of Chemotherapy

To better understand the long-term effects of chemotherapy, the researchers evaluated 23 cancer patients. The patients had solid tumor or hematologic malignancies, were 3-80 years of age, and had received a variety of chemotherapeutic agents. Collectively, they were exposed to 21 drugs spanning the main chemotherapy classes, including alkylating agents, platinum agents, antimetabolites, topoisomerase I and II inhibitors, vinca alkaloids, and cytotoxic antibiotics.

June 2025  
Renal+Urology

Chemotherapy




## Low-intensity shockwave therapy for erectile dysfunction

Low-intensity shockwave therapy (LiSWT) is a new way of treating erectile dysfunction using sound waves to help improve blood flow to the penis. No existing systematic reviews comparing LiSWT to placebo or other therapies for treating erectile dysfunction have used rigorous Cochrane methodology.

[More Info](#)  
July 2025  
Today

URO

ED




## A new way to treat cancer: Targeting the Hedgehog protein's hidden weakness

These researchers are focused on a biological pathway called Hedgehog signaling. The key to improving cancer treatment may lie in developing new drugs that more effectively block this process of Hedgehog signaling—beginning with the generation of the Hedgehog ligand, the protein that triggers the entire pathway.

July 2025  
MedicalXpress

Hedgehog



## Cellular signature explains why some prostate tumors resist standard treatments


Treatments such as enzalutamide, which is an androgen receptor pathway inhibitor (ARPI), are standard of care for advanced prostate cancer. While many patients have long-term good response to the drugs, some will derive no benefit whatsoever. These "extreme non-responder" patients die much more quickly from prostate cancer.

[More Info Here](#)

July 2025  
MedicalXpress

Cellular

There's a lot riding on your prostate health...  
KNOW THE SCORE.



ClarityDX Prostate uses clinical and blood-based biomarkers to determine a patient's risk of having clinically significant prostate cancer to help patients and their physicians make more informed healthcare decisions.

## ClarityDX technology can be used to predict the risk of disease.

When it comes to a cancer diagnosis, Clarity means peace of mind. And when it comes to prostate cancer detection, it takes the right data to deliver that Clarity.

ClarityDX Prostate is a clinically proven decision support tool that uses a machine learning platform to calculate an accurate prostate cancer risk score from clinical data and multiple blood-based PSA test results (5-7).

If you have an elevated PSA, or a suspicion of prostate cancer, ClarityDX Prostate may be right for you. ClarityDX Prostate takes the fear and uncertainty out of prostate cancer screening.

**ClarityDX**



## AI-based tool can 'measure' cancer aggressiveness and paves the way for new therapies

The machine learning model can predict the aggressiveness of certain tumors by identifying specific proteins. It generates a stemness index ranging from zero to one, with zero indicating low aggressiveness and one indicating high aggressiveness. As the index increases, the cancer tends to become more aggressive and resistant to drugs and more likely to recur.

July 2025  
Oncology & Cancer

**Aggressive**

**Thank you to our Sponsors and Community Partners**

**Disclaimer:** The PROSTAID Calgary Society website & newsletter provides news and information about prostate issues and activities of the organization. While information is presented about prostate cancer and related issues, it is not intended as a substitute for professional medical advice, diagnosis, or treatment. PROSTAID Calgary Society recommends that you seek the advice of your physician or other qualified health professionals regarding questions you may have about any medical condition. Topics on

PROSTAID Calgary Society's website & newsletter are presented to inform you and we encourage you to seek professional medical advice before starting any treatment.

P.O. Box 72126  
R.P.O. Glenmore Landing  
Calgary, Alberta T2V 5H9



[Unsubscribe](#)